학술논문
The Role of Registers in Increasing Knowledge and Improving Management of Children and Adolescents Affected by Familial Hypercholesterolemia: the LIPIGEN Pediatric Group
Document Type
article
Author
Marta Gazzotti; Manuela Casula; Stefano Bertolini; Maria Elena Capra; Elena Olmastroni; Alberico Luigi Catapano; Cristina Pederiva; the LIPIGEN Paediatric Group; Massimiliano Allevi; Marcello Arca; Renata Auricchio; Maurizio Averna; Davide Baldera; Giuseppe Banderali; Andrea Bartuli; Giacomo Biasucci; Claudio Borghi; Patrizia Bruzzi; Raffaele Buganza; Paola Sabrina Buonuomo; Paolo Calabrò; Sebastiano Calandra; Francesca Carubbi; Arturo Cesaro; Francesco Cipollone; Nadia Citroni; Giuseppe Covetti; Annalaura Cremonini; Sergio D’Addato; Maria Del Ben; Maria Donata Di Taranto; Giuliana Fortunato; Roberto Franceschi; Federica Galimberti; Simonetta Genovesi; Antonina Giammanco; Liliana Grigore; Ornella Guardamagna; Arcangelo Iannuzzi; Gabriella Iannuzzo; Lorenzo Iughetti; Lidia Lascala; Fabiana Locatelli; Sara Madaghiele; Giuseppe Mandraffino; Massimo Raffaele Mannarino; Bucci Marco; Lorenzo Maroni; Ilenia Minicocci; Giuliana Mombelli; Sandro Muntoni; Fabio Nascimbeni; Gianfranco Parati; Angelina Passaro; Chiara Pavanello; Fabio Pellegatta; Francesco Massimo Perla; Matteo Pirro; Livia Pisciotta; Arturo Pujia; Francesco Purrello; Elisabetta Rinaldi; Riccardo Sarzani; Roberto Scicali; Patrizia Suppressa; Patrizia Tarugi; Sabrina Verachtert; Giovanni Battista Vigna; Josè Pablo Werba; Alberto Zambon; Sabina Zambon; Maria Grazia Zenti
Source
Frontiers in Genetics, Vol 13 (2022)
Subject
Language
English
ISSN
1664-8021
Abstract
Pathology registers can be a useful tool to overcome obstacles in the identification and management of familial hypercholesterolemia since childhood. In 2018, the LIPIGEN pediatric group was constituted within the Italian LIPIGEN study to focus on FH subjects under 18 years. This work aimed at discussing its recent progress and early outcomes. Demographic, biochemical, and genetic baseline characteristics were collected, with an in-depth analysis of the genetic defects. The analysis was carried out on 1,602 children and adolescents (mean age at baseline 9.9 ± 4.0 years), and almost the whole cohort underwent the genetic test (93.3%). Overall, the untreated mean value of LDL-C was 220.0 ± 97.2 mg/dl, with an increasing gradient from subjects with a negative (N = 317; mean untreated LDL-C = 159.9 ± 47.7 mg/dl), inconclusive (N = 125; mean untreated LDL-C = 166.4 ± 56.5 mg/dl), or positive (N = 1,053; mean untreated LDL-C = 246.5 ± 102.1 mg/dl) genetic diagnosis of FH. In the latter group, the LDL-C values presented a great variability based on the number and the biological impact of involved causative variants. The LIPIGEN pediatric group represents one of the largest cohorts of children with FH, allowing the deepening of the characterization of their baseline and genetic features, providing the basis for further longitudinal investigations for complete details.